Tesamorelin is often discussed as a peptide therapy for reducing stubborn abdominal fat.
However, determining the correct dose is not as simple as choosing a number from an online protocol.
There is no established tesamorelin dosage for general fat loss or weight loss.
Current branded formulations have different once-daily doses for adults with HIV-associated lipodystrophy.
Older studies used a different formulation and dose, which is why conflicting numbers frequently appear online.
The right tesamorelin dosage depends on the exact product, medication concentration, treatment plan and prescribing instructions.
Tesamorelin Dosage at a Glance
- There is no universally established tesamorelin dosage for general fat loss.
- EGRIFTA WR is dosed at 1.28 mg once daily.
- EGRIFTA SV is dosed at 1.4 mg once daily.
- The frequently mentioned 2 mg dose comes from an older formulation used in clinical studies.
- Tesamorelin has primarily been studied for visceral abdominal fat, not substantial scale-weight loss.
- Syringe units depend on the concentration of the prepared medication.
- Increasing the dose does not necessarily produce more fat loss and may raise the risk of side effects.
What Is the Typical Tesamorelin Dosage for Fat Loss?
The typical tesamorelin dosage depends on the formulation being used.
| Formulation or treatment context | Dose commonly referenced | What to know |
|---|---|---|
| EGRIFTA WR | 1.28 mg once daily | The labeled dose is contained in 0.16 mL after the product is prepared as directed |
| EGRIFTA SV | 1.4 mg once daily | The labeled dose is contained in 0.35 mL after preparation |
| Earlier clinical studies | 2 mg once daily | Studies used a previous 1 mg-per-vial formulation |
| Other prescribed formulations | Varies | Concentration, injection volume and schedule depend on the prescription |
EGRIFTA WR and EGRIFTA SV have different strengths, preparation instructions, injection volumes and storage requirements.
One product should not be substituted for the other using the same milligram or syringe-volume instructions.
Some pharmacies may prepare tesamorelin at different concentrations.
However, clinical results obtained with one branded formulation and dosing schedule may not apply identically to every differently prepared formulation.
Patients should follow the dose printed on their prescription rather than applying a dosage chart found online.
How Does Tesamorelin Work for Fat Loss?
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone, also called GHRH or growth hormone-releasing factor.
It works by signalling the pituitary gland to release more of the body’s own growth hormone.
This can increase levels of insulin-like growth factor 1, commonly called IGF-1.
Growth hormone and IGF-1 influence several processes related to metabolism, tissue growth and how the body stores and breaks down fat.
Tesamorelin has shown its clearest effect on visceral adipose tissue.
This is the deeper fat located inside the abdomen and around the internal organs.
It should not be viewed as a medication that directly melts fat from a particular visible area.
It changes hormonal signals that may affect visceral-fat metabolism over time.
Because tesamorelin affects growth hormone and IGF-1, treatment may require laboratory monitoring.
Taking more does not automatically produce faster or better results.
Is There a Tesamorelin Dosage for Weight Loss?
There is no standard tesamorelin dosage for weight loss in the general population.
Tesamorelin is used to reduce excess abdominal fat in adults with HIV-associated lipodystrophy.
Current medication information states that it is not intended for weight-loss management.
This does not mean tesamorelin has no effect on body composition.
It means reducing a specific type of abdominal fat may not produce a large change in total body weight.
A person could potentially experience:
- A smaller waist measurement
- A change in abdominal shape
- Reduced visceral fat
- Changes in body composition
- Little or no significant change on the scale
Someone whose main goal is losing a substantial amount of total body weight may need a different treatment approach.
Tesamorelin Fat Loss vs Weight Loss
Fat loss and weight loss are related, but they do not describe the same outcome.
Weight loss means a reduction in total body weight.
The number on the scale can change because of fat, muscle, water, glycogen and other tissues.
Fat loss refers specifically to a reduction in body fat.
Tesamorelin has primarily been studied for its effects on visceral fat rather than overall body weight or general subcutaneous fat.
| Clinical finding | What studies reported |
| Visceral abdominal fat | Average reductions of approximately 14% to 18% after 26 weeks |
| Waist circumference | Average reductions of approximately 2 to 3 centimetres |
| Total body weight | Little average change |
| After treatment stopped | Some visceral fat returned in participants who discontinued treatment |
These results came from studies involving adults with HIV-associated lipodystrophy.
They should not be interpreted as guaranteed results for everyone seeking abdominal fat loss.
What Type of Belly Fat Does Tesamorelin Target?
The abdomen contains two main types of fat.
Visceral fat
Visceral fat is located deeper inside the abdomen and surrounds internal organs.
Excess visceral fat is associated with several metabolic health concerns.
Tesamorelin’s strongest clinical evidence involves reductions in this type of fat.
Subcutaneous fat
Subcutaneous fat is located directly beneath the skin.
It is the softer or pinchable fat that many people think of when they describe belly fat.
Tesamorelin should not be assumed to reduce subcutaneous abdominal fat or fat throughout the body to the same degree as visceral fat.
This difference is one reason a person may not see the exact physical change expected, even when internal visceral-fat measurements improve.
Why Do Some Sources Recommend 2 mg of Tesamorelin?
The commonly referenced 2 mg tesamorelin dosage comes from an earlier formulation and the clinical studies used to evaluate it.
Participants in the pivotal studies received 2 mg once daily using a 1 mg-per-vial formulation.
Much of the published information about tesamorelin and visceral-fat reduction comes from those studies.
Newer formulations use different strengths and doses:
- EGRIFTA WR: 1.28 mg once daily
- EGRIFTA SV: 1.4 mg once daily
- Historical EGRIFTA formulation: 2 mg once daily
A lower milligram number does not necessarily mean the newer formulation provides less tesamorelin exposure.
Current prescribing information reports similar systemic exposure between 1.28 mg of EGRIFTA WR and 2 mg of the older formulation.
A person should not automatically use 2 mg simply because it appears in an older study, article or dosing guide.
Tesamorelin Dosage in Milligrams vs Syringe Units
Tesamorelin doses may be described in milligrams, millilitres or syringe units.
These measurements are related, but they are not interchangeable.
Milligrams measure the amount of tesamorelin.
Millilitres measure the volume of liquid.
Syringe units represent volume markings on certain syringes.
The number of syringe units needed for a particular dose depends on the concentration of the medication.
For example, medication prepared at 8 mg per mL requires a different injection volume than medication prepared at 4 mg per mL.
Two vials may contain the same total amount of tesamorelin but require different syringe markings after preparation.
For EGRIFTA WR, the labeled 1.28 mg dose is contained in 0.16 mL after the product is prepared exactly as directed.
That conversion should not be used for another product or concentration.
There is no safe universal answer such as “tesamorelin is always 10, 20 or 30 units.”
Patients should use the syringe marking supplied by their prescriber or pharmacy.
Does Tesamorelin Dosage Depend on Body Weight?
Current branded tesamorelin doses are not calculated according to body weight.
The medication instructions provide fixed daily doses rather than a milligram-per-kilogram formula.
They also do not provide different standard doses for men and women.
However, body weight is only one factor that may be considered before prescribing treatment.
A provider may also review:
- The location and amount of abdominal fat
- IGF-1 levels
- Fasting blood glucose
- HbA1c
- Diabetes risk
- Current medications
- Cancer history
- Pituitary function
- Pregnancy status
- Previous reactions to injectable medications
- Overall treatment goals
Even when a product has a fixed labeled dose, a medical assessment is needed to determine whether treatment is appropriate.
How Often Is Tesamorelin Taken?
Current branded formulations are injected under the skin once daily.
This is known as a subcutaneous injection.
Some online tesamorelin protocols recommend schedules such as five days on treatment followed by two days off.
Others suggest taking tesamorelin for a set number of months before completing an off-treatment cycle.
These schedules are not universal instructions found in current branded prescribing information.
Changing the frequency or skipping days may affect how consistently tesamorelin influences growth hormone and IGF-1.
Patients should follow the schedule on their prescription rather than adopting a cycle intended for a different formulation or treatment plan.
What Is the Best Time to Take Tesamorelin?
Current branded prescribing information directs patients to use tesamorelin once daily but does not establish one required time of day for everyone.
It also does not state that every patient must inject tesamorelin:
- At bedtime
- First thing in the morning
- On an empty stomach
- A specific number of hours after eating
A prescribing provider may recommend a particular schedule based on the treatment plan and medication instructions.
The dose should generally be taken at a consistent time according to the prescription.
Patients should ask their provider what to do if they miss a dose rather than doubling the next injection.
Where Is Tesamorelin Injected?
Current branded instructions direct patients to inject tesamorelin under the skin of the abdomen.
The injection site should be rotated so the same spot is not used every day.
Patients should avoid injecting into:
- The belly button
- Bruised skin
- Scar tissue
- Irritated areas
- Inflamed skin
- Areas with lumps or changes in texture
- The exact same spot repeatedly
A clinician or pharmacist should demonstrate how to prepare and inject the medication before the first self-administered dose.
Preparation instructions vary between tesamorelin products.
Patients should use the directions provided with their specific medication rather than following an injection video or guide created for another formulation.
How Long Does Tesamorelin Take to Reduce Visceral Fat?
Tesamorelin does not normally produce a major body-composition change after only a few injections.
Clinical studies evaluated changes over approximately 26 weeks.
At that point, average visceral-fat reductions were about 14% to 18%, while average waist reductions were approximately 2 to 3 centimetres.
These numbers are study averages, not individual guarantees.
A person’s tesamorelin results timeline may be influenced by:
- Baseline visceral-fat levels
- Consistency with treatment
- Nutrition
- Alcohol intake
- Exercise habits
- Sleep quality
- Blood sugar regulation
- Hormone and IGF-1 responses
- Other health conditions
- The specific formulation being used
Weight alone may not show whether visceral fat is changing.
Waist measurements or appropriate body-composition assessments may provide more useful information.
What Happens When You Stop Tesamorelin?
Some of the visceral-fat reduction associated with tesamorelin may be lost after treatment ends.
In extension studies, participants who continued taking tesamorelin generally maintained more of their visceral-fat reduction.
Participants who were switched from tesamorelin to a placebo experienced increases in visceral fat during the following months.
This does not mean abdominal fat returns at the same rate for every person.
Nutrition, activity level, metabolic health, alcohol intake and other treatments may affect what happens after discontinuation.
However, tesamorelin should not be viewed as a brief cycle that permanently removes abdominal fat.
Before beginning treatment, patients should understand:
- How progress will be measured
- When follow-up testing will occur
- How long treatment may continue
- What side effects should be reported
- What could lead to a dose adjustment
- What could lead to discontinuation
Can a Higher Tesamorelin Dose Cause More Fat Loss?
Taking a higher tesamorelin dose does not necessarily produce faster or greater fat loss.
Tesamorelin increases growth hormone secretion and may raise IGF-1.
Increasing the dose without medical guidance can increase exposure without providing additional benefit.
Possible concerns associated with treatment include:
- Elevated IGF-1
- Fluid retention
- Swelling
- Joint discomfort
- Muscle pain
- Numbness or tingling
- Carpal tunnel symptoms
- Changes in blood glucose
- Injection-site reactions
- Allergic reactions
The dose should not be increased simply because the number on the scale has not changed.
Tesamorelin is not intended to produce rapid scale-weight loss, and a lack of weight change does not necessarily show whether visceral fat has changed.
A clinician should review the treatment response before any dosage adjustment is considered.
What Monitoring May Be Needed During Tesamorelin Treatment?
Monitoring helps determine whether tesamorelin is producing an appropriate response without causing unwanted changes.
IGF-1 levels
Tesamorelin may increase IGF-1.
Persistently elevated levels may lead a provider to reassess whether treatment should continue.
Blood glucose and HbA1c
Tesamorelin may affect glucose regulation.
Blood sugar should be evaluated before treatment and monitored during treatment, particularly in people with diabetes or an increased risk of developing it.
Body-composition changes
Scale weight does not provide a complete picture of visceral-fat changes.
A provider may consider waist circumference, body-composition measurements and other clinical indicators.
Side effects
Patients should report persistent swelling, joint discomfort, numbness, tingling, significant injection-site reactions or possible allergic symptoms.
Overall treatment response
A provider may reconsider treatment when there is no meaningful improvement, laboratory values become concerning or side effects outweigh the expected benefits.
Long-term cardiovascular safety has not been established for current branded tesamorelin treatment.
Who Should Not Use Tesamorelin?
Tesamorelin is not appropriate for everyone.
Current prescribing information lists contraindications that include:
- Pregnancy
- Active malignancy
- Known hypersensitivity to tesamorelin or its ingredients
- Disruption of the hypothalamic-pituitary axis caused by pituitary surgery, a pituitary tumour, head irradiation, head trauma or hypopituitarism
People with a history of cancer, diabetes, impaired glucose regulation or other significant medical conditions should discuss their complete medical history with a licensed provider.
Patients should also provide a complete list of:
- Prescription medications
- Over-the-counter medications
- Vitamins
- Supplements
- Other injectable treatments
This allows the provider to evaluate whether tesamorelin is appropriate and identify potential interactions or overlapping effects.
Finding the Right Tesamorelin Dosage for Fat Loss
The appropriate tesamorelin dosage cannot be determined from a fat-loss goal alone.
The formulation, medication concentration, health history, laboratory results and monitoring plan all matter.
Current branded doses include 1.28 mg once daily for EGRIFTA WR and 1.4 mg once daily for EGRIFTA SV.
The older 2 mg daily dose comes from a previous formulation and should not automatically be applied to current or differently prepared products.
BHRT Delivered provides personalized telehealth consultations for eligible patients across the United States.
A licensed provider can review your health history, discuss your body-composition goals and explain the dosing instructions for the specific treatment prescribed.
FAQs: Tesamorelin Dosage for Fat Loss
How much tesamorelin should I take for fat loss?
There is no universal tesamorelin dosage for general fat loss. Current branded doses are 1.28 mg once daily for EGRIFTA WR and 1.4 mg once daily for EGRIFTA SV. Older studies used 2 mg daily with a different formulation. Follow the instructions for the exact product you receive.
Is tesamorelin taken every day?
Current branded tesamorelin formulations are injected once daily. Alternative schedules, including five days on and two days off, are not universal instructions and should only be followed when specifically prescribed.
Does tesamorelin cause weight loss?
Tesamorelin may reduce visceral abdominal fat without producing substantial weight loss. Clinical studies found measurable reductions in visceral fat but little average change in total body weight.
How long does tesamorelin take to work?
Changes in visceral fat develop gradually. Clinical studies measured meaningful changes over approximately 26 weeks, although individual timelines vary based on baseline body composition, treatment consistency and other health factors.
What are the benefits of tesamorelin vs sermorelin?
Tesamorelin has stronger clinical evidence for reducing visceral abdominal fat, while sermorelin is generally used to stimulate natural growth hormone production. The better option depends on the treatment goal, health history and provider’s assessment.
What are the benefits of tesamorelin vs CJC-1295?
Tesamorelin has more clinical evidence for visceral-fat reduction than CJC-1295. CJC-1295 also stimulates growth hormone and IGF-1, but research supporting its use specifically for fat loss is more limited.
What are the benefits of AOD 9604 vs tesamorelin?
Tesamorelin has stronger human evidence for reducing visceral abdominal fat. AOD 9604 is designed to influence fat metabolism without the same growth hormone response, but its evidence for meaningful human fat loss is more limited.
